Theravance Biopharma, Inc.
NASDAQ:TBPHBiotechnology
-$0.07 today
- Market cap
- $882.64M
- Beta
- 0.18
- P/E (TTM)
- 7.4
- EPS (TTM)
- $2.23
Volume 10.02M
Average 0.43M
TBPH EBITDA Margin
EBITDA as a percentage of revenue.
Theravance Biopharma, Inc.NASDAQ: TBPH
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -28.4%
EBITDA Margin was -28.4% in Q1 FY2026, up 56.6 pp from a year earlier. On a trailing-twelve-month basis it was 129.8%, up 193.9 pp year over year. Over 3 fiscal years it widened by 275.9 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether next quarter's EBITDA Margin reaches the consensus estimate of 29.7%, a -253.8 pp change from the same quarter last year.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -28.4%-192.2 pp QoQ
- Last fiscal yearDec 2025
- 127.7%+187.4 pp YoY
- LTMMar 2026
- 129.8%+193.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +56.6 pp | -253.8 pp | -310.4 pp |
| 1 year | +187.4 pp | — | — |
| 3 years | +275.9 pp | -60.1 pp | -336.0 pp |
| 5 years | -18.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 127.7%
- Year-over-year change
- +187.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 127.7% | +187.4pp |
| FY2024 | 2024-12-31 | -59.7% | +30.2pp |
| FY2023 | 2023-12-31 | -89.9% | +58.2pp |
| FY2022 | 2022-12-31 | -148.2% | +272.8pp |
| FY2021 | 2021-12-31 | -420.9% | — |
EBITDA Margin vs competitors
How TBPH compares with its peers on the latest reported figures
- TBPH's LTM Mar 2026 EBITDA Margin of 129.8% is the highest of the 6 companies compared; the peer median is -287.6%.
- Its year-over-year change of +193.9 pp is the 2nd highest of 5, against a peer median of +22.0 pp.
- Over three fiscal years its change of +275.9 pp compares with a peer median of -178.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 129.8% | +193.9 pp | +275.9 pp | |
| LTM Mar 2026 | -18.8% | +79.6 pp | +22480.3 pp | |
| LTM Mar 2026 | -57.7% | -35.6 pp | +0.1 pp | |
| LTM Mar 2026 | -287.6% | -298.7 pp | — | |
| LTM Mar 2026 | -515.2% | — | -356.4 pp | |
| LTM Mar 2026 | -669.6% | +2109.2 pp | -668.6 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding TBPH) | -287.6% | +22.0 pp | -178.2 pp | |
Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.31M | 51.35M | 57.42M | 64.38M | 107.46M |
| Cost of Revenue | 193.66M | 63.39M | 40.62M | 37.64M | 5.52M |
| Gross Profit | (138.35M) | (12.05M) | 16.8M | 26.74M | 101.95M |
| Gross Margin | -250.1% | -23.5% | 29.3% | 41.5% | 94.9% |
| Research & Development | 201.55M | 70.07M | 46.34M | 38.05M | 37.41M |
| Selling, General & Admin | 99.3M | 67.07M | 70.45M | 69.17M | 73.65M |
| Operating Expenses | 119.44M | 79.91M | 72.84M | 73.69M | 115.2M |
| Depreciation & Amortization | 4.81M | 3.04M | 2M | 3.62M | 5.52M |
| EBITDA | (232.83M) | (76.08M) | (51.65M) | (38.45M) | 137.22M |
| EBITDA Margin | -420.9% | -148.2% | -89.9% | -59.7% | 127.7% |
| Operating Income | (257.78M) | (91.96M) | (56.04M) | (46.95M) | (13.25M) |
| Operating Margin | -466.1% | -179.1% | -97.6% | -72.9% | -12.3% |
| Interest Income | 1.11M | 8.55M | 9.12M | 4.88M | 0 |
| Interest Expense | 8.55M | 6.37M | 2.35M | 2.55M | 2.46M |
| Other Income / Expenses | (7.44M) | (858K) | 6.77M | 2.34M | 142.49M |
| Income Before Tax | (265.22M) | (92.82M) | (49.27M) | (44.61M) | 129.25M |
| Pre-Tax Margin | -479.5% | -180.8% | -85.8% | -69.3% | 120.3% |
| Income Tax Expense | (151K) | 9K | 5.92M | 11.8M | 23.35M |
| Net Income | (199.43M) | 872.13M | (55.19M) | (56.42M) | 105.9M |
| Net Margin | -360.6% | 1698.5% | -96.1% | -87.6% | 98.5% |
| EPS (Basic) | (2.87) | (1.26) | (1.00) | (1.15) | 2.10 |
| EPS (Diluted) | (2.87) | (1.26) | (1.00) | (1.15) | 2.06 |
| Weighted Avg Shares | 69.46M | 73.59M | 55.3M | 48.85M | 50.32M |
| Weighted Avg Shares (Diluted) | 69.46M | 73.59M | 55.3M | 48.85M | 51.51M |
Theravance Biopharma, Inc.
NASDAQ:TBPH
Intrinsic Alpha fair value
Locked
Current Price
$17.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.